9MW 2921
Alternative Names: 9MW-2921Latest Information Update: 07 Sep 2023
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Aug 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in China (IV) (NCT05990452)
- 21 Jul 2023 National Medical Products Administration approves IND application for 9MW 2921 in advanced solid tumors
- 05 Feb 2023 Preclinical trials in Solid tumours in China (Parenteral) before February 2023